A Study to Evaluate Cenvacibart (REGN7508) for Secondary Stroke Prevention in Adult Participants

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 6106 participants.

Also called NCT07876492

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose prevention
Phase
Phase 3
Enrolled
  • 6,106 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07876492
  • EU CT 2026-527406-20-00
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07876492. Randomized; quadruple masking; primary purpose prevention. Start 2026-11-20 (anticipated); primary completion 2029-12-15 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Evaluate Cenvacibart (REGN7508) for Secondary Stroke Prevention in Adult Participants
Acronym
ROXI-DAISEN
Condition
Secondary Stroke
Intervention (Drug)
Cenvacibart
Intervention (Drug)
Placebo
Lead sponsor
Regeneron Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct07876492
Content hash
c60b77dcee6b79c0471dee07caf415317e4de16dc9f1cb01409e248aea370913